Cognition Therapeutics Inc (CGTX)

Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)June 24, 2026 8:46 AM
IH Market News Cognition Therapeutics (NASDAQ:CGTX) shares gained 5% after the company announced that it had received written feedback from the U.S. Food and Drug Administration regarding the development pathway for zervimesine (CT1812) in patients with psychosis associated with dementia with Lewy bodies. The regulatory update provided clarity on the company’s proposed late-stage development strategy and was viewed positively by investors. FDA Aligns With Company on Pivotal Study Design According to Cognition Therapeutics, the FDA agreed that psychosis linked to dementia with Lewy bodies could serve as an approvable indication and aligned with the company on several key components of a pivotal clinical trial intended to support a future New Drug Application (NDA). The company expects to launch its registrational program in mid-2027. The feedback represents an important milestone for the development of zervimesine and provides a clearer regulatory pathway toward potential commercialization. Planned Phase 3 Trial Targets Psychosis Symptoms The proposed Phase 3 study will focus on patients with dementia with Lewy bodies who experience psychosis-related symptoms, including hallucinations and delusions. Individuals receiving stable treatment with off-label antipsychotic medications will be eligible to participate in the study. Following screening, participants will be randomly assigned to receive either a once-daily 100 mg oral dose of zervimesine or a placebo over a nine-month treatment period. The trial is designed to evaluate whether zervimesine can meaningfully improve psychosis symptoms in this underserved patient population. Novel Endpoint Discussions Continue Cognition said it will continue working closely with the FDA on the analytical and statistical framework surrounding the use of the neuropsychiatric inventory as the primary endpoint for the pivotal study. The neuropsychiatric inventory is expected to play a central role in measuring treatment effects on hallucinations, delusions and other behavioral symptoms associated with dementia with Lewy bodies psychosis. If accepted, the endpoint would represent a novel primary measure in a registrational study for this condition. Phase 2 Results Provide Foundation The Phase 3 program will build on data generated from Cognition’s Phase 2 COG1201 “SHIMMER” study involving patients with mild-to-moderate dementia with Lewy bodies. In that trial, zervimesine demonstrated improvements in psychosis symptoms compared with placebo when evaluated using the neuropsychiatric inventory. The company recently reported additional analyses showing that treatment with zervimesine slowed the progression of hallucinations and delusions by 89% relative to placebo. These findings have helped support the company’s decision to advance the candidate into a pivotal development program. Additional Data Expected in July Cognition Therapeutics plans to present further analyses from the SHIMMER trial at the Alzheimer’s Association International Conference in July. The presentation will focus on zervimesine’s effects on the hallucination and delusion components of the neuropsychiatric inventory, providing investors and researchers with additional insight into the drug’s potential clinical benefits. The upcoming data release is expected to be closely watched as the company continues preparing for its planned Phase 3 program and future regulatory submissions. Cognition Therapeutics stock priceThe post Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX) appeared first on US Editors. Original: Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)

cgtx.....................................https://stockcharts.com/sc3/ui/?s=CGTX&p=w&b=5&g=0&id=p86431144783

Share price at this time $1.68, Change +$0.23 (+15.52%). GLTA

Long Tail Up on 17 June 2026. GLTA
At Close $1.42 +$0.16 (+12.70%).

High Pole Warning on 2 June 2026. GLTA
At Close $1.35 share price up +$0.10 (+8.00%).

Long Tail Up on 20 May 2026. GLTA
Right at this time share price up +$0.19 (+16.67%) Go Go Go!

Low Pole Reversal on 20 May 2026. GLTA

Low Pole Reversal on 30 Apr 2026. GLTA

Ascending Triple Top Breakout on 21 Apr 2026. GLTA

In Low Pole Reversal pattern/mode since 14 Apr 2026. GLTA

Double Top Breakout on 8 Apr 2026. GLTA

CGTX...........................https://stockcharts.com/sc3/ui/?s=CGTX&p=w&b=5&g=0&id=p86431144783

Double Top Breakout on 25 Feb 2026. GLTA

Low Pole Reversal on 24 Feb 2026. GLTA

Bearish Signal Reversed on 10 Feb 2026. GLTA

Bearish Signal Reversed on 16 Jan 2026. GLTA

Double Top Breakout on 7 Jan 2026. GLTA

Low Pole Reversal on 2 Jan 2026. GLTA
Repeat. We shall see. Happy New Year 2026. An even year.

Low Pole Reversal on 26 Dec 2025. GLTA

Double Bottom Breakdown on 23 Dec 2025. BLTA
PS: It all depends on Traders/Trading dynamic to change the picture suddenly, in the short term.
C'est La Vie in the market. Same happened with CMG few weeks ago.

Bearish Signal Reversed on 22 Dec 2025. GLTA

Low Pole Reversal on 18 Dec 2025. GLTA

CGTX..............................................................https://stockcharts.com/sc3/ui/?s=CGTX&p=W&b=5&g=0&id=p86431144783

Ascending Triple Top Breakout on 3 Dec 2025. GLTA

Cognitively think it due for a Penny or Two 1.68 + 4%

High Pole Warning on 2 Dec 2025. GLTA

Double Top Breakout on 26-Nov-2025. GLTA

Low Pole Reversal on 24-Nov-2025. GLTA

Low Pole Reversal on 24-Oct-2025. GLTA

In High Pole Warning mode since 13-Oct-2025. GLTA

Ascending Triple Top Breakout on 7-Oct-2025. GLTA

High Pole Warning on 6-Oct-2025. BLTA
Share price adjustment likely.

Ascending Triple Top Breakout on 3-Oct-2025. GLTA

High Pole Warning on 2-Oct-2025. BLTA
Share price likely to readjust.
We shall see.

Double Top Breakout on 1-Oct-2025. GLTA
Chart is improving therefor interesting.

Low Pole Reversal since 26-Sep-2025 GLTA
Looks interesting. I feel bullish at this time.
It could be the beginning of a new price advance. Bullish, imo.

Bearish Triangle Breakdown on 25-Sep-2025.
Accumulation opportunity. GLTA

Double Bottom Breakdown on 19-Sep-2025. BLTA

Long Tail Down on 12-Sep-2025. BLTA
This is positive. Looking forward to a price breakout, hopefully soon.

Day order to buy shares at $2.40 ps filled. GLTA

High Pole Warning on 8-Sep-2025. BLTA
This popped up and good my order was not filled.
Oppty to buy at lower price.

Bearish Signal Reversed on 5-Sep-2025. GLTA

PS: Entered day order to buy shares at $2.48
Important and urgent need for work in recognition healing meds.

Descending Triple Bottom Breakdown on 4-Sep-2025. BLTM

PS: Short term tech view as of this time. I think this is a promising stock.
We shall see. GLTA

Today's volume is on track to be lighter than usual, with 2,205,680 shares having traded so far.
The On Balance Volume indicator (OBV) is bullish.
The slope of the indicator is positive and suggests that buyers are presently more active than sellers as of 1:12 PM ET Tuesday, 09/02/2025 GLTA

PS: Entered day (limit) order buy at $2.24. This in case share price drops given the larger market environment.

Day order to buy shares at $2.50 per share filled. GLTA

PS: Yesterday I sold half my shares at $3.00 per share,
with 263% profits.
Today's purchase added 33.33% more shares in Port,
with average cost now at $1.94.
I will add more shares in Port, should share price fall lower.

Today's volume is on track to be lighter than usual, with 3,487,765 shares having traded so far. The On Balance Volume indicator (OBV) is bullish. The slope of the indicator is positive and suggests that buyers are presently more active than sellers as of 1:33 PM ET Wednesday, 08/27/2025

Long Tail Down on 26-Aug-2025.
Following the price adjustment it is likely the up-move may continue.
Today's volume is on track to be lighter than usual, with 7,313,269 shares having traded so far.
The On Balance Volume indicator (OBV) is bullish. The slope of the indicator is positive and suggests that buyers are presently more active than sellers as of 12:59 PM ET Tuesday, 08/26/2025

We shall see. GLTA

PS: Let's hope the resistance at or about $2.70 will hold to support the price. Demand volume needs to grow.

CGTX...................................................https://stockcharts.com/h-sc/ui?s=CGTX&p=W&b=5&g=0&id=p86431144783

It only makes sense for a correction and the chart says so.

However, it looks like a "rolling" correction is happening... as it continues its journey. Cwazy!

We shall see how this daring journey unfolds.

Long Tail Up since 20-Aug-2025.
This is a warning of a likely price adjustment. It makes sense.
I am up 213% up in price.
Being a risk taking spirit, I'm defying the law of gravity at this time, lol. GLTA

PS: The last 10-days have seen significant volume in CGTX, with average daily volume above the average for the last year. Today's volume is no exception; with 20,362,341 shares having been traded already. The On Balance Volume indicator (OBV) is bullish. The slope of the indicator is positive and suggests that buyers are presently more active than sellers as of 12:45 PM ET Monday, 08/25/2025